Robert Morton, MD
Psychiatry · Ada, OKNPI 1336222504
Payments from drug & device makers
Across 3,880 payments — averaging $498.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$483K
- Teva Pharmaceuticals USA, Inc.$305K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$284K
- Alkermes, Inc.$277K
- AbbVie$180K
- Johnson & Johnson$160K
- plus $246K from 26 others
Across 2 payments — averaging $5925.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$12K
What the payments were for
- Consulting fees$112,2926%
- Speaking & faculty fees$1,660,22486%
- Travel & lodging$107,1096%
- Food & beverage$54,5253%
- Education$6250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 732 | $483,133 |
| Teva Pharmaceuticals USA, Inc. | 460 | $305,109 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 376 | $284,085 |
| Alkermes, Inc. | 351 | $276,956 |
| AbbVie(2 entities) | 265 | $179,520 |
| Johnson & Johnson | 432 | $160,293 |
| E.r. Squibb & Sons, L.L.C. | 279 | $155,314 |
| Vanda Pharmaceuticals Inc. | 68 | $33,221 |
| Sunovion Pharmaceuticals Inc. | 249 | $21,433 |
| Otsuka America Pharmaceutical, Inc. | 298 | $19,521 |
| Acadia Pharmaceuticals Inc | 23 | $11,318 |
| Lundbeck LLC | 122 | $1,383 |
| Takeda Pharmaceuticals U.S.A., Inc. | 102 | $1,021 |
| Supernus Pharmaceuticals, Inc. | 13 | $825 |
| Avanir Pharmaceuticals, Inc. | 40 | $454 |
| Corium, LLC | 16 | $208 |
| Harmony Biosciences LLC | 8 | $202 |
| Axsome Therapeutics, Inc. | 12 | $150 |
| Indivior Inc. | 9 | $141 |
| UCB, Inc. | 7 | $133 |
| Sumitomo Pharma America, Inc. | 4 | $67 |
| Medtronic | 1 | $49 |
| Collegium Pharmaceutical, Inc. | 2 | $44 |
| Urovant Sciences Inc | 2 | $36 |
| Jazz Pharmaceuticals Inc. | 1 | $33 |
| Merck | 2 | $31 |
| Bioxcel Therapeutics, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $13 |
| Shire North American Group Inc | 1 | $11 |
| Neuronetics, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$662,847
- INGREZZA$474,404
- LYBALVI$425,320
- CAPLYTA$279,433
- VRAYLAR$175,723
- ARISTADA INITIO$165,712
- INVEGA SUSTENNA$154,962
- INVEGA TRINZA$154,118
- Austedo XR$147,972
- COBENFY$129,524
- UZEDY$124,170
- Fanapt$32,396
- AUSTEDO$26,274
- LATUDA$20,233
- REXULTI$15,919
- NUPLAZID$10,708
- QELBREE$597
- Wakix$105
How this compares
$1,934,774 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 874 | $6,361,435 |
| Austedo XrDeutetrabenazine | 642 | $4,751,170 |
| VraylarCariprazine Hcl | 2,852 | $3,221,005 |
| AustedoDeutetrabenazine | 360 | $2,422,317 |
| NuplazidPimavanserin Tartrate | 414 | $1,893,175 |
| AristadaAripiprazole Lauroxil | 494 | $1,476,625 |
| TrintellixVortioxetine Hydrobromide | 3,432 | $1,386,894 |
| Invega SustennaPaliperidone Palmitate | 396 | $1,332,503 |
| CaplytaLumateperone Tosylate | 854 | $1,140,547 |
| LybalviOlanzapine/Samidorphan Malate | 705 | $1,045,681 |
| Riluzole | 5,861 | $1,000,435 |
| Clozapine | 10,076 | $816,476 |
| NuedextaDextromethorphan Hbr/Quinidine | 508 | $585,396 |
| RexultiBrexpiprazole | 460 | $541,586 |
| TrulicityDulaglutide | 536 | $529,674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Uzedy | $305,109 | $7,325,1371,040 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $483,133 | $6,361,435874 claims |
| AbbVieVraylar, Linzess | $179,520 | $3,332,8703,094 claims |
| Alkermes, Inc.Aristada, Lybalvi | $276,956 | $2,522,3061,199 claims |
| Acadia Pharmaceuticals IncNuplazid | $11,318 | $1,893,175414 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $160,293 | $1,588,774424 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,021 | $1,386,8943,432 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $284,085 | $1,140,547854 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $19,521 | $877,945577 claims |
| Lilly USA, LLCTrulicity, Olanzapine, Mounjaro | $19 | $723,6365,780 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $454 | $585,396508 claims |
| Novo NordiskOzempic, Rybelsus | $13 | $582,163570 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Ada
- Louise ThurmanOklahoma City$6.2M
- Veronique SebastianOklahoma City$3.8M
- Marvin PeytonOklahoma City$3.2M
- Sarah LandTulsa$2.8M
- Willis HollowayOklahoma City$1.4M
- Courtney NixonOklahoma City$1.2M
- Surinder RandhawaOklahoma City$142K
- Adonis Al BotrosOklahoma City$73K
- Ondria GleasonTulsa$68K
- Martin PaulusTulsa$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.